| Autor: |
Tatsumi S; Department of Molecular Nutrition, Institute of Health Bioscience, University of Tokushima Graduate School, Japan., Nagamoto K, Ogata M, Miyamoto K |
| Jazyk: |
japonština |
| Zdroj: |
Clinical calcium [Clin Calcium] 2015 Jul; Vol. 25 (7), pp. 1043-7. |
| DOI: |
CliCa150710431047 |
| Abstrakt: |
Osteocytes orchestrate bone resorption and bone formation by controlling osteoclast and osteoblast activity. On the other hand, osteocytes secret FGF23 (fibroblast growth factor 23), FGF23 acts on the kidney to control phosphate homeostasis. Sclerostin is also released from osteocytes and it regulated osteoblast activity through Wnt/β-catenin pathway. Therefore, an antibody that targets sclerostin is currently in phase- III clinical trials for the treatment of osteoporosis and it is expected as new therapeutics. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
